Takeda

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). A very rare, inherited blood clotting disorder, cTTP is caused by a disease-causing mutation in the ADAMTS13 gene, which is responsible for making an enzyme, also named ADAMTS13, […]

Takeda has revealed favourable interim results from its Phase III crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). cTTP is an ultra-rare, chronic and debilitating blood clotting disorder caused by a deficiency in ADAMTS13 enzyme. Clinical presentation of cTTP lies […]

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s vaccine candidate Qdenga for active immunisation against dengue infection from four years of age.  Dengue is the fastest spreading mosquito-borne virus and was recognised by the World Health Organization (WHO) in 2019 as one of the top ten threats to […]

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Takeda’s EXKIVITY (mobocertinib) for patients in Great Britain with a rare and aggressive form of non-small cell lung cancer (NSCLC).   The authorisation means that EXKIVITY (mobocertinib) will be made available as a treatment for adult patients with epidermal growth factor […]

Lu Rahman looks at how opportunities are growing in Japanese drug development and where innovation is coming from. Japan is a fascinating drug discovery and development market. A strong pharmaceutical sector (some reports place it second globally behind the US), an ageing population and a tranche of expertise, put the country in a good position. […]